1-3 of 3
Uday Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Uday Kumar, Srikant Viswanadha, PhD, Silvia Laura Locatelli, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Lucia Morello, Massimo Magagnoli, Armando Santoro, Andrés J.M. Ferreri, MD
Journal: Blood
Blood (2016) 128 (22): 3011.
https://doi.org/10.1182/blood.V128.22.3011.3011
Published: 2016
Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Thamila Saheb, Uday Kumar, Srikant Viswanadha, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Armando Santoro, MD, Silvia Laura Locatelli, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD PhD, Andres J.M. Ferreri
Journal: Blood
Blood (2015) 126 (23): 1495.
https://doi.org/10.1182/blood.V126.23.1495.1495
Published: 2015
Journal Articles

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Lydia Scarfò, Prajak J Barde, MBBS, MD, Claudia Fazi, PhD, Uday Kumar, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD, Andres J.M. Ferreri, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3043.
https://doi.org/10.1182/blood.V124.21.3043.3043
Published: 2014